Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ESG 206

Next Previous
Drug Profile

ESG 206

Alternative Names: ESG-206

Latest Information Update: 04 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Escugen Biotechnology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Idiopathic thrombocytopenic purpura
  • Phase I B-cell lymphoma

Most Recent Events

  • 03 Feb 2026 Shanghai Escugen Biotechnology plans a phase II trial for Sjogren's syndrome in China (IV, Infusion), in March 2026 (NCT07375524)
  • 06 Dec 2025 adverse event, efficacy, pharmacokinetic and pharmacodynamic data from a phase I/II trial in Idiopathic thrombocytopenic purpura presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025)
  • 12 Sep 2025 Shanghai Escugen Biotechnology withdraws a phase-I trials in B-cell lymphoma (IV) due to the company's development strategy adjustment (NCT05263739)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top